Pilot Study Reports Beneficial Effects of Ambroxol for Fibromyalgia Pain

Pilot Study Reports Beneficial Effects of Ambroxol for Fibromyalgia Pain
Results from a pilot clinical study published in the journal Clinical Rheumatology showed that ambroxol may help manage pain in fibromyalgia patients. Ambroxol is mainly known as a mucolytic and expectorant agent. It has been used for decades in the treatment of various airway disorders, helping to restore the normal clearance mechanisms of the respiratory tract. Previous studies have shown that ambroxol has the capacity to block the response of sodium channels, which are responsible for the transmission of pain sensations caused by nerve damage or dysfunction (neuropathic pain). The drug was shown to be 13 times more potent compared to other known calcium channel blockers, such as benzocaine, Xylocaine (lidocaine), and Mexitil (mexiletine). It's been previously suggested that fibromyalgia could have a neuropathic nature. Indeed, a study performed by researchers from Mexico found that some patients with fibromyalgia presented a mutation on a sodium channel gene associated with neuropathic pain signals. These findings support the hypothesis that sodium channel blocker agents might have a therapeutic potential for this medical condition. The authors of the study, "Ambroxol for fibromyalgia: one group pretest-posttest open-label pilot study," tried to identify the add-on benefits of ambroxol to standard fibromyalgia treatment regimens. A total of 25 patients with fibromyalgia were given Ambr
Subscribe or to access all post and page content.